Fjarde AP Fonden Fourth Swedish National Pension Fund Takes Position in Insmed, Inc. $INSM

Fjarde AP Fonden Fourth Swedish National Pension Fund purchased a new stake in Insmed, Inc. (NASDAQ:INSM) during the fourth quarter, Holdings Channel.com reports. The firm purchased 50,500 shares of the biopharmaceutical company’s stock, valued at approximately $8,789,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. CoreCap Advisors LLC purchased a new position in shares of Insmed in the 4th quarter valued at $27,000. GraniteShares Advisors LLC purchased a new position in shares of Insmed in the 4th quarter valued at $30,000. CIBC Private Wealth Group LLC increased its holdings in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 53 shares during the period. SBI Securities Co. Ltd. increased its holdings in shares of Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 166 shares during the period. Finally, Larson Financial Group LLC boosted its position in shares of Insmed by 137.0% in the 4th quarter. Larson Financial Group LLC now owns 256 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 148 shares in the last quarter.

Insmed Stock Performance

Insmed stock opened at $94.22 on Monday. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80. Insmed, Inc. has a 52 week low of $70.57 and a 52 week high of $212.75. The company has a market capitalization of $20.42 billion, a price-to-earnings ratio of -16.39 and a beta of 0.79. The stock has a 50-day moving average price of $130.45 and a 200 day moving average price of $154.65.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. The firm had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The company’s revenue was up 229.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.42) earnings per share. Sell-side analysts anticipate that Insmed, Inc. will post -2.56 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on INSM. Stifel Nicolaus raised their price objective on Insmed from $205.00 to $208.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Guggenheim lowered their price objective on Insmed from $230.00 to $226.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Morgan Stanley raised Insmed from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $166.00 to $212.00 in a research report on Monday, March 30th. Royal Bank Of Canada lowered their price objective on Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a research report on Friday. Finally, Truist Financial lowered their price objective on Insmed from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Insmed presently has a consensus rating of “Moderate Buy” and an average target price of $210.50.

Insider Buying and Selling

In other Insmed news, insider Michael Alexander Smith sold 2,159 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $220,800.93. Following the completion of the transaction, the insider directly owned 39,454 shares of the company’s stock, valued at approximately $4,034,960.58. The trade was a 5.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO William Lewis sold 7,605 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total value of $777,763.35. Following the completion of the transaction, the chief executive officer directly owned 265,432 shares of the company’s stock, valued at $27,145,730.64. The trade was a 2.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 160,482 shares of company stock worth $24,438,193 over the last ninety days. 2.10% of the stock is owned by corporate insiders.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.